Cryo-Cell International financials
$4.05−2.64%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 May 31 | Q1 '26 Feb 28 | Q4 '25 Nov 30 | Q3 '25 Aug 31 | Q2 '25 May 31 | Q1 '25 Feb 28 | Q4 '24 Nov 30 | Q3 '24 Aug 31 | Q2 '24 May 31 | Q1 '24 Feb 29 | Q4 '23 Nov 30 | Q3 '23 Aug 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M | $7.7M | $7.8M | $7.8M | $7.9M | $8.0M | $8.0M | $8.1M | $8.0M | $7.9M | $7.9M | $7.9M |
| Gross profit | $6.1M | $6.0M | $6.1M | $6.0M | $6.1M | $6.0M | $6.4M | $5.9M | $6.0M | $5.8M | $5.9M | $5.7M |
| Gross margin | 78.4% | 78.4% | 77.9% | 77.0% | 76.6% | 75.1% | 79.6% | 73.6% | 74.8% | 73.7% | 74.3% | 72.6% |
| Operating income | $1.2M | $765.1K | -$4.0M | $1.9M | $1.5M | $1.1M | $185.7K | $1.4M | $1.7M | $821.2K | -$16.2M | $1.2M |
| Net income | $554.6K | $47.1K | -$3.8M | $749.4K | $355.8K | $282.9K | -$1.9M | $1.1M | $655.8K | $556.2K | -$11.2M | $680.6K |
| Net margin | 7.1% | 0.6% | −48.7% | 9.6% | 4.5% | 3.5% | −23.2% | 13.0% | 8.2% | 7.1% | −142.1% | 8.6% |
| Diluted EPS | $0.07 | $0.01 | $-0.48 | $0.09 | $0.04 | $0.03 | $-0.23 | $0.13 | $0.08 | $0.07 | $-1.36 | $0.08 |
| EBITDA | $1.4M | $1.0M | $635.1K | $2.1M | $1.7M | $1.3M | $434.6K | $1.6M | $1.8M | $907.3K | $19.1K | $1.6M |
| Operating cash flow | $1.8M | $651.8K | $1.3M | $2.5M | $707.0K | $954.1K | $2.2M | $2.4M | $1.8M | -$356.9K | $3.3M | $1.7M |
| Free cash flow | $1.8M | $584.8K | $1.2M | $2.5M | $644.6K | $892.0K | $2.1M | $2.3M | $21.5K | -$814.6K | $1.6M | -$1.6M |
| Diluted shares | 8.1M | 8.1M | 7.9M | 8.1M | 8.1M | 8.2M | 8.1M | 8.2M | 8.2M | 8.3M | 8.2M | 8.3M |
Balance sheet
| Period end | May 31 | Feb 28 | Nov 30 | Aug 31 | May 31 | Feb 28 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $507.3K | $249.7K | $319.0K | $265.2K | $137.5K | $223.1K |
| Short-term investments | $2.7M | $2.7M | $3.0M | $3.0M | $4.3M | $3.3M |
| Total debt | $9.0M | $10.8M | $11.4M | $12.5M | $16.0M | $13.9M |
| Total assets | $60.7M | $60.9M | $61.7M | $63.2M | $64.4M | $64.4M |
| Total liabilities | $78.5M | $79.3M | $80.3M | $78.0M | $80.0M | $79.0M |
| Shareholders' equity | -$17.8M | -$18.4M | -$18.6M | -$14.8M | -$15.6M | -$14.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology